Stockreport

Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

Jaguar Health, Inc.  (JAGX) 
US:NASDAQ Investor Relations: jaguarhealth.gcs-web.com/investor-overview
PDF License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 monthsService agreement of up to $5.0 million payable in unregistered [Read more]